![](https://library.celltelligence.com/wp-content/uploads/2023/08/Screenshot-2023-08-17-at-21.04.38.png)
$0
Precision and Imugene Agree on Terms for the Transfer of Azer-cel; Precision to Deprioritize its Cell Therapy Franchise
On Tuesday, August 15, Precision Biosciences announced (press release) a strategic transaction with Imugene for the exclusive WW licensing of azer-cel (PBCAR0191; allogeneic CD19 CAR-T) in oncology, which also included option to develop up to 3 other cancer programs. Additionally, Imugene disclosed (press release) its intention to continue azer-cel’s Ph1/2a trial in ≥3L NHL and r/r ALL, while planning the initiation of a potentially registrational trial in 2024. Below, Celltelligence provides insights on azer-cel’s transaction agreement, while analyzing the possible therapeutic potential of the combination of the licensed CD19 CAR-T with Imugene’s proprietary onCARlytics platform.